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Objectives. We sought to study the relationship between sur-
vival and right ventricular ejection fraction (RVEF) in a subgroup
of patients with moderate congestive heart failure (CHF).
Background. It has been demonstrated that RVEF is an inde-
pendent predictor of survival in patients with advanced CHF.
Methods. Cardiopulmonary exercise testing and radionuclide
angiography (to determine right and left ventricular ejection
fraction) were prospectively performed in 205 consecutive patients
with moderate CHF (140 patients in New York Heart Association
[NYHA] class II, 65 in class III).
Results. Left ventricular ejection fraction was 29.3% 6 10.1%,
RVEF was 37.5% 6 14.6% and peak oxygen consumption (VO2)
was 16.2 6 5.4 ml/min/kg (60.2% 6 19% of maximal predicted
VO2). After a median follow-up period of 755 days, there were 44
cardiac-related deaths, 3 deaths from noncardiac causes and 15
transplantations of whom 2 were urgent; 1 patient was lost to
follow-up. Multivariate analysis showed that three variables—
NYHA classification, percent of maximal predicted VO2 and
RVEF—were independent predictors of both survival and event-
free cardiac survival. Left ventricular ejection fraction and peak
VO2 normalized to body weight had no predictive value. The
event-free survival rates from cardiovascular mortality and urgent
transplantation at 1 year were 80%, 90% and 95% in patients with
an RVEF <25%, with a RVEF >225% and <35% and with a RVEF
>235%, respectively. At 2 years, survival rates were 59%, 77% and
93% in the same subgroups, respectively.
Conclusions. In addition to the NYHA classification and to the
percent of maximal predicted VO2, RVEF is an independent
predictor of survival in patients with moderate CHF.
(J Am Coll Cardiol 1998;32:948–54)
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Congestive heart failure (CHF) remains a leading cause of
morbidity and mortality (1). While previous studies have
investigated the relative value of different parameters in pre-
dicting survival, the majority were conducted in populations
with severe cardiac failure, notably in patients awaiting heart
transplantation (2–6). The majority of patients presenting with
heart failure have moderate CHF. Nevertheless, the annual
mortality rate in this less severely affected group remains high
at around 10% per year. To improve the management of these
patients, it is important to define parameters that could predict
survival. Di Salvo et al. (7) recently demonstrated the indepen-
dent prognostic value of the right ventricular ejection fraction
(RVEF) in a subgroup of patients with advanced heart failure.
The potential value of this parameter has not been reported in
patients with moderate heart failure. To answer this question,
we conducted a prospective study in this subgroup of patients.
Our results demonstrate that RVEF is a powerful independent
predictor of survival in patients with stable and moderate heart
failure.
Methods
Study population. From November 1991 to June 1996, 205
consecutive stable patients with left ventricular systolic dys-
function were studied. Patients in sinus rhythm who had a left
ventricular ejection fraction (LVEF) #45% (determined by
radionuclide angiography) and who were stable and ambula-
tory for at least 3 months were included in the study. Patients
were excluded if they had had unstable angina or recent (,6
months) myocardial infarction, percutaneous coronary angio-
plasty or coronary bypass grafting. Patients with significant
pulmonary disease were also excluded as well as patients with
intermittent claudication, ventricular tachycardia or angina
during exercise that could lead to a nonmaximal exercise.
Transplantation was not planned in any patients at the time of
inclusion in the study. During the inclusion period, 45 patients
were screened and excluded for the following reasons: atrial
fibrillation, 33 patients; nonmaximal exercise test, 12 patients.
Of these 45 patients, 8 died from a cardiovascular origin, 2 had
a noncardiovascular death and 1 patient underwent a nonur-
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gent transplantation. Of the 205 patients included in the study,
34 were women and the mean age was 54 6 11 years. Most of
the patients were in class II of the New York Heart Association
(NYHA) functional classification (140; 68%) and 65 patients
(32%) were in class III. The etiology of the left ventricular
systolic dysfunction was ischemic cardiomyopathy in 80 pa-
tients (39%) and nonischemic cardiomyopathy in 121 patients
(59%). The four other patients (2%) refused coronary angiog-
raphy.
Exercise protocol. Exercise was performed in the morning
after a light, standard meal (30 minutes to 2 hours before the
test) and on an upright electromagnetically braked bicycle
(Meditronic 35 Hellige [Freiburg, Germany] and from January
1995, Ergo-Metrics 900 Ergoline [Bitz, Germany]) using a
continuous protocol (30 watts for the first 3 min, with subse-
quent increments of 10 watts/min). Medications were not
withdrawn before the test. Patients cycled at a constant rate of
60 rpm throughout the test. They were allowed to continue
until respiratory exchange ratio (defined as the ratio between
oxygen consumption [VO2] and carbon dioxide production)
was .1. Exercise was terminated when the patient was unable
to continue, which was the result of either dyspnea and/or
leg/general fatigue. Heart rate was continuously recorded on a
12-lead electrocardiogram (Marquette Electronics Inc., Mil-
waukee, Wisconsin, Case 15). Blood pressure was measured
every 2 min and at peak exercise with a mercury sphygmoma-
nometer. The data for gas exchange were collected on a
breath-by-breath basis using a computerized system (Medical
Graphics Corporation, St. Paul, Minnesota, CPX system). The
oxygen fraction was measured using a permanent zirconium
oxide electrochemical cell and the carbon dioxide fraction was
measured using a dual-beam infrared absorption chamber. A
complete calibration (using standard gas mixtures) was per-
formed prior to each exercise test. Anaerobic threshold was
determined by the V slope method and by analyzing ratio of
minute ventilation against VO2 and ratio of minute ventilation
against carbon dioxide production. Peak VO2 and peak carbon
dioxide production were defined as the highest average value
during 10 s obtained during the last minute of exercise. Oxygen
pulse was defined as the ratio of VO2 against heart rate.
Predicted value of maximal VO2 was calculated using Wasser-
man’s equation, normalizing maximal VO2 for age, gender,
weight and height (8).
Radionuclide determination. Radionuclide angiography
was performed at rest in the supine position with use of an in
vivo red blood cell labeling method. An equilibrium multigated
acquisition was initiated after the injection of 20 mCi of
technetium-99m. Imaging was performed in two views on a
DST camera (Sopha Medical, Twinsburg, Ohio): the left
anterior oblique projection that best visualized the interven-
tricular septum and a 70° left anterior oblique projection.
Studies were acquired on a 64 3 64 matrix with 16 frames per
cardiac cycle for a preset count of 400,000 cps. Right ventric-
ular ejection fraction and LVEF were calculated by automated
detection of end diastolic and end systolic contours with
manual correction if necessary. All the studies were performed
by the same investigator (C.F.-H.) who was not aware of the
results of the cardiopulmonary exercise test.
End points and follow-up. Follow-up was performed by
direct examination or by contact with the general practitioner
or the cardiologist. All the patients were followed up for at
least 1 year except if a major end point terminated the
follow-up. Major end points were total events (mortality and
transplantation), total mortality, cardiovascular events (cardio-
vascular death and transplantation) and cardiovascular mor-
tality (that included cardiovascular death and urgent transplan-
tation [United Network for Organ Sharing status 1
{UNOS1}]) (9).
Statistics. Results are presented as mean 6 SD. Differ-
ences between groups were assessed by analysis of variance
and by unpaired Student’s t tests followed by the Student–
Newman–Keuls test. Discrete variables were compared using a
chi-square analysis. Relationships between variables were stud-
ied by a linear regression analysis.
A Kaplan–Meier method was performed to estimate the
cumulative survival. We stratified the population study into
two subgroups on the basis of the median value of the variable
tested for quantitative variable and in the different subgroups
for qualitative variables. A comparative log rank test was used
to compare the survival rates of the different subgroups. A
stepwise multivariate Cox proportional hazards analysis was
performed to determine the independent predictors of cardiac
survival (freedom from cardiovascular mortality and urgent
transplantation). We included in the model variables that were
significant at a level of 0.1 in the univariate analysis. Quanti-
tative variables were entered as continuous variables. Systolic
pulmonary arterial pressure (SPAP), estimated by the maximal
velocity of the tricuspid regurgitation on a echoDoppler study
(VingMed, Horten, Norway, CFM 750), was included in the
model as a qualitative variable, coded 0 if SPAP #35 mm Hg,
coded 1 if SPAP was between 35 and 45 mm Hg and coded 2
if SPAP $45 mm Hg. In 35 patients there was no significant
tricuspid regurgitation (pulsed Doppler mode guided by color
Doppler mode) and these patients were coded 0. Previous
studies have demonstrated that patients without tricuspid
regurgitation had normal pulmonary pressure (10). In another
model we included the SPAP as a quantitative variable,
excluding the 35 patients with no tricuspid regurgitation.
Etiology was entered as a qualitative variable, coded 0 for
nonischemic cardiomyopathy, coded 1 for ischemic cardiomy-
opathy and coded 2 for the four women who refused the
Abbreviations and Acronyms
CHF 5 congestive heart failure
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
RVEF 5 right ventricular ejection fraction
SPAP 5 systolic pulmonary artery pressure
UNOS 5 United Network for Organ Sharing
VO2 5 oxygen consumption
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coronary angiography. These four patients were still alive at
the end of the follow-up period. Statistics were performed with
the SAS software version 6.08 (SAS Institute Inc., Cary, North
Carolina). A value of p , 0.05 was considered statistically
significant.
Results
Patients. Clinical characteristics of the study population
are summarized in Table 1. Most of the patients were taking
angiotensin-converting enzyme inhibitors (194, 94.6%), diuret-
ics (165, 80.5%) and digoxin (129, 62.9%). Other medications
were nitrates (94, 45.8%), amiodarone (67, 32.7%), aspirin (83,
40.5%), anticoagulants (80, 39%), beta blocking agents (34,
16.6%) and calcium inhibitors (9, 4.4%). The mean LVEF was
29.3% 6 10.1% (median: 29%), the mean RVEF was 37.5% 6
14.6% (median: 39%), the mean peak VO2 normalized to body
weight was 16.2 6 5.4 ml/min/kg (median: 15.8 ml/min/kg) and
the mean percent of maximal predicted value was 60.2% 6
19% (median: 60%).
Relationship between RVEF and other parameters. Coef-
ficients of correlation between peak VO2 and RVEF were
determined in the whole population and in subgroups divided
according to etiology (Table 2). All the coefficients of correla-
tion were similar, suggesting that etiology did not modify the
relationship between exercise capacity and RVEF. We also
studied the relationship between RVEF and SPAP (excluding
the 35 patients with no significant tricuspid regurgitation).
Figure 1 shows the scatterplot between RVEF and %peak
VO2 (top) and between RVEF and SPAP (bottom). Although
the p values were statistically significant, coefficients of corre-
lation were always ,0.4 with wide 95% prediction intervals.
Survival analysis. During a median follow-up period of
722 days (49 to 1,940 days), there were 44 cardiac-related
deaths, 15 transplantations of whom 2 were urgent (UNOS1),
3 deaths from noncardiac causes (malignant diseases) and 1
patient was lost to follow-up. The cardiovascular event rates
(cardiovascular mortality and transplantation) at 1 and 2 years
were 10% and 21%, respectively. The cardiovascular mortality
rates (cardiovascular mortality and UNOS1) at 1 and 2 years
were 10% and 19%, respectively. Figure 2 shows the event-free
survival curve from cardiovascular mortality and urgent trans-
plantation for the whole study population. Table 1 summarizes
the differences between patients without events and patients
with either a cardiovascular death or an urgent transplantation.
Table 3 summarizes the differences in the two subgroups of
patients divided according to the median value of the RVEF
(median value: 39%). Figure 3 shows the event-free survival
curves from cardiovascular mortality and urgent transplanta-
tion in the two subgroups of patients divided according to the
median values of the RVEF (top), the LVEF (middle) and the
percent of maximal predicted VO2 (bottom).
Multivariate Cox analysis. The stepwise multivariate Cox
analysis selected three independent predictors of cardiac sur-
vival: the NYHA classification, the percent of maximal pre-
Table 1. Characteristics in the Whole Population, in Survivors and
in Nonsurvivors (Cardiovascular Mortality and Urgent
Transplantation)
Whole
Population Survivors Nonsurvivors
p
Value
n 205 159 46
Gender (M/F) 171/34 131/28 40/6 0.61
Age (yr) 54 6 11 54.2 6 10.6 53.2 6 12.5 0.58
Ischemic/nonischemic* 80/121 61/94 19/27 0.85
NYHA II/III 140/65 121/38 19/27 ,0.0001
LVEF (%) 29.3 6 10.1 30.4 6 9.9 25.4 6 10 0.003
RVEF (%) 37.5 6 14.6 40 6 13.8 28.9 6 14 ,0.0001
LVEDD (mm) 65.9 6 8.55 65.6 6 8.2 66.8 6 9.8 0.41
SPAP (mm Hg)† 39.3 6 14.9 38 6 15 43 6 14 0.052
Duration of exercise (s) 587 6 224 616 6 228 496 6 200 0.0016
Rest HR (beats/min) 88.7 6 18.7 87.3 6 18.3 92 6 19.3 0.14
Peak HR (beats/min) 142 6 28 143 6 27 140 6 23 0.49
Rest SBP (mm Hg) 122 6 21 123 6 20 119 6 23 0.25
Peak SBP (mm Hg) 157 6 33 161 6 32 144 6 31 0.002
VO2 at AT (ml/min) 771 6 309 810 6 304 609 6 287 0.0001
Peak VO2 (ml/min) 1,226 6 477 1,285 6 459 1,036 6 472 0.0015
Peak VO2 (ml/min/kg) 16.2 6 5.4 17 6 5.13 13.7 6 5.5 0.0002
%Peak VO2 60.2 6 19 63 6 18 50.2 6 19.5 ,0.0001
Peak RER 1.18 6 0.12 1.18 6 0.12 1.2 6 0.14 0.34
Peak O2 pulse
(ml/min/beats)
9.55 6 13.5 9.1 6 15.2 7.34 6 2.68 0.0006
%Peak O2 pulse 71.9 6 24.3 75 6 24 60.7 6 20.6 0.0003
*The four patients who refused angiography were excluded; †the 35 patients
with nonsignificant tricuspid regurgitation were excluded. AT 5 anaerobic
threshold; F 5 females; HR 5 heart rate; LVEDD 5 left ventricular end
diastolic diameter; LVEF 5 left ventricular ejection fraction; M 5 males;
NYHA 5 New York Heart Association; O2 5 oxygen; RER 5 respiratory
exchange ratio; RVEF 5 right ventricular ejection fraction; SBP 5 systolic blood
pressure; SPAP 5 systolic pulmonary artery pressure; VO2 5 oxygen consump-
tion.
Table 2. Coefficients of Correlation and Respective p Values
Between RVEF and Other Variables in the Whole Population, in
Patients With Ischemic Cardiomyopathy and in Patients With
Nonischemic Cardiomyopathy
Variables Whole Population Ischemic* Nonischemic*
Peak VO2 r 5 0.21 r 5 0.22 r 5 0.27
p 5 0.0029 p 5 0.05 p 5 0.0024
Peak VO2/kg r 5 0.17 r 5 0.18 r 5 0.26
p 5 0.014 p 5 0.1 p 5 0.004
%Peak VO2 r 5 0.29 r 5 0.36 r 5 0.32
p , 0.0001 p 5 0.0009 p 5 0.0003
Peak O2 pulse r 5 0.28 r 5 0.30 r 5 0.27
p , 0.0001 p 5 0.0071 p 5 0.0031
% Peak O2 pulse r 5 0.26 r 5 0.29 r 5 0.24
p 5 0.0001 p 5 0.0098 p 5 0.0085
SPAP† r 5 20.31 r 5 20.29 r 5 20.36
p , 0.0001 p 5 0.03 p 5 0.0001
LVEF r 5 0.39 r 5 0.395 r 5 0.40
p , 0.0001 p 5 0.0003 p , 0.0001
*The four patients who refused angiography were excluded; †the 35 patients
with nonsignificant tricuspid regurgitation were excluded. Abbreviations as in
Table 1.
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dicted VO2 and the RVEF (Table 4). Neither LVEF nor peak
VO2 normalized to body weight were predictors of survival.
The result of the stepwise multivariate Cox analysis was
similar if we included in the model the following parameters in
this order: NYHA classification, LVEF, peak VO2 normalized
to body weight, %peak VO2 and RVEF. Right ventricular
ejection fraction remained the only significant independent
predictor of event-free survival from cardiovascular mortality
and urgent transplantation (chi-square 5 3.93, p 5 0.0475),
followed by NYHA classification (chi-square 5 2.84, p 5 0.09).
Left ventricular ejection fraction, %peak VO2 and peak
VO2/kg were not predictors of survival.
The result was similar if we entered in the model the SPAP
as a continuous variable (excluding the 35 patients with
nonsignificant tricuspid regurgitation) or as a qualitative vari-
able. If we performed another multivariate Cox analysis with a
stratification according to etiology, the best predictor of event-
free survival from cardiovascular mortality and urgent trans-
plantation was the RVEF (chi-square 5 19.9, p 5 0.0001),
followed by the NYHA classification (chi-square 5 11, p 5
0.0009). If the study population was stratified according to the
NYHA classification, independent predictors of major cardiac
events were the RVEF (chi-square 5 11.5, p 5 0.0007) and the
peak VO2/kg (chi-square 5 4.7, p 5 0.03). In the 140 class II
patients, event-free survival from cardiovascular mortality and
urgent transplantation were 93% and 99% at 1 year and 81%
and 98.5% at 2 years in the two subgroups divided according to
the median value of the RVEF, respectively. In the 65 class III
patients, the corresponding values were 72% and 87% at 1 year
and 56% and 75% at 2 years.
New York Heart Association classification, RVEF and
%peak VO2 were also independent predictors of cardiovascu-
lar mortality and transplantation (urgent and nonurgent)
whether we considered the date of transplantation or the date
the patient was put on the waiting list for transplantation.
Figure 1. Relationship between RVEF and percent of maximal pre-
dicted VO2 (top) and between RVEF and SPAP (bottom). The 35
patients with nonsignificant tricuspid regurgitation were excluded.
Figure shows individual values, regression line and 95% prediction
intervals.
Figure 2. Event-free survival curve from cardiovascular mortality and
urgent transplantation (UNOS1) for the whole population.
Table 3. Differences Between Patients Divided According to the
Median Value of the RVEF (Median Value: 39%)
RVEF
#39%
RVEF
.39% p Value
n 107 98
Gender (M/F) 87/20 84/14 0.51
Age (yr) 52 6 11.2 56.2 6 10.6 0.0063
NYHA II/III 63/44 77/21 0.004
Ischemic/nonischemic* 33/72 47/49 0.017
LVEF (%) 25.7 6 9.92 33.2 6 8.9 ,0.0001
LVEDD (mm) 68 6 8.8 63.7 6 7.7 0.0003
SPAP (mm Hg)† 42.6 6 15.3 34.4 6 12.8 0.0003
Duration of exercise (s) 558 6 219 623 6 232 0.04
Rest HR (beats/min) 91.3 6 19.2 85.2 6 17.3 ,0.019
Peak HR (beats/min) 145 6 26.5 140 6 26.6 0.2
Rest SBP (mm Hg) 117 6 21 127 6 19 ,0.0001
Peak SBP (mm Hg) 148 6 32 166 6 31 ,0.0001
VO2 at AT (ml/min) 705 6 333 831 6 274 0.0043
Peak VO2 (ml/min) 1,151 6 494 1,315 6 434 0.013
Peak VO2 (ml/min/kg) 15.5 6 5.94 17 6 4.6 0.042
%Peak VO2 55.7 6 20.3 64.95 6 15.8 0.0004
Peak RER 1.21 6 0.13 1.15 6 0.1 ,0.0001
Peak O2 pulse (ml/min/beats) 7.92 6 2.86 9.57 6 3.16 0.0001
%Peak O2 pulse 65.8 6 23 78.5 6 24.1 0.0002
*The four patients who refused angiography were excluded; †the 35 patients
with nonsignificant tricuspid regurgitation were excluded. Abbreviations as in
Table 1.
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Figure 4 shows the receiver operating characteristic curve
of RVEF in determining cardiovascular mortality and urgent
transplantation at 1 year. The value of 35% has the highest
sensitivity and specificity (70% and 58%, respectively). Figure
5 shows the event-free survival curves from cardiovascular
mortality and urgent transplantation in three subgroups of
patients divided according to the value of the RVEF (,25%,
between 25% and 35% and $35%). The survival rates at 1 year
were 80%, 90% and 95% in patients with an RVEF ,25%,
with an RVEF between 25% and 35% and with an RVEF
$35%, respectively. At two years, the survival rates in these
three subgroups were 59%, 77% and 93%, respectively.
Discussion
The major and novel finding of the present study was that
RVEF is an independent predictor of survival in a large group
of patients with stable and moderate CHF. In addition, given
the large number of patients studied, we were able to analyze
the relationship between RVEF, exercise capacity and SPAP.
Relationship between RVEF and other variables. The right
ventricle is very sensitive to load, and SPAP is an important
determinant of right ventricular function. We demonstrated
that there was a significant but weak correlation between
RVEF and SPAP in patients with moderate heart failure. The
coefficient of correlation was 0.3 with wide 95% confidence
intervals (Fig. 1). This is not surprising since our patients were
stable and is not inconsistent with previous studies that failed
to demonstrate a correlation between SPAP and right ventric-
ular function in patients with heart failure. Schulman et al. (11)
did not find a relationship between RVEF and SPAP in
patients awaiting heart transplantation. Lewis et al. (12) dem-
onstrated that SPAP was not correlated with right ventricular
dilation in patients with dilated cardiomyopathy. Right ventric-
ular ischemia in ischemic cardiomyopathy (13) or right ven-
Figure 4. Receiver operating characteristic curve of the RVEF in
determining event-free survival from cardiovascular mortality and
urgent transplantation at 1 year.
Figure 3. Event-free survival curves from cardiac mortality and urgent
transplantation (UNOS1) in the two subgroups of patients divided
according to the median value of the RVEF (top), of the LVEF
(middle) and of the percent of maximal predicted VO2 (bottom).
Table 4. Results of the Multivariate Stepwise Cox Analysis
Parameters Chi-square p Value
Total events %peak VO2 32.9 0.0001
NYHA 7.82 0.0052
RVEF 4.27 0.039
Total mortality %peak VO2 17 0.0001
RVEF 7.75 0.0059
Cardiovascular events NYHA 31.67 0.0001
%peak VO2 15.2 0.0001
RVEF 6.19 0.013
Cardiovascular mortality
and UNOS1
NYHA 23 0.0001
RVEF 10.96 0.0009
%peak VO2 4.25 0.039
UNOS1 5 United Network for Organ Sharing status 1. Other abbreviations
as in Table 1.
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tricular involvement in patients with idiopathic cardiomyopa-
thy could explain the absence of a relationship between RVEF
and SPAP. Our multivariate analysis did not select SPAP as an
independent predictor of survival, whether we included this
parameter as a continuous variable or as a qualitative variable.
The SPAP was estimated noninvasively during an echoDoppler
evaluation. It is possible that the results might be different if
SPAP were measured invasively. However, previous studies
have demonstrated a good correlation between values of SPAP
determined by right heart catheterization and those estimated
by echoDoppler (10,14). We also analyzed the relationship
between RVEF and exercise capacity, assessed by the estima-
tion of the peak VO2. In our study, which represents the largest
series of patients published to date, the relationship between
peak VO2 and RVEF is statistically significant. However, this
relationship is weak, with a coefficient of correlation less than
0.3 and wide 95% confidence intervals (Fig. 1). While it has
been suggested that this relationship is more marked in
patients with ischemic cardiomyopathy, our results do not
support this hypothesis (15). All the coefficients of correlation
were similar whatever the etiology of heart failure (Table 2).
Our results are thus in agreement with those of Clark et al. (16)
who demonstrated that there was no relationship between
RVEF and either peak VO2 or the VE/VCO2 slope. Di Salvo
et al. (7) concluded that RVEF was correlated with peak VO2
with an r 5 0.37. Although confidence intervals were not given
in the report by Di Salvo et al., the accompanying figure
suggests that they were wide, as in the present study and that
of Clark et al. (16). The mechanism of exercise intolerance in
patients with heart failure is very complex and is related to
several parameters (cardiac, vascular, lung function and mus-
cle metabolism). It is difficult to conclude that RVEF plays the
most important role in determining exercise capacity in pa-
tients with heart failure.
Survival analysis. The most important result of our study is
the independent prognostic information derived from the
determination of the RVEF in a subgroup of patients with
stable heart failure. Previous studies have demonstrated a
similar result but in patients with advanced heart failure, most
of whom were awaiting heart transplantation (7,17–19). The
mortality rate of our population was around 10% per year
compared to almost 40% at 1 year in the study by Di Salvo et
al. (7). Most of our patients were in class II of the NYHA
classification (68%); the vast majority (94.6%) were taking
angiotensin-converting enzyme inhibitors and all the patients
were ambulatory. In the study by Di Salvo et al. (7), 24% of the
67 patients were in NYHA class II, the mean LVEF was 22%
6 7%, the mean RVEF was 29% 6 11%, the mean peak VO2
and %peak VO2 were 11.8 6 4.2 ml/min/kg and 38% 6 12%,
respectively. All these values were different in our study,
supporting the fact that our patients had moderate heart
failure. If the analysis was restricted to NYHA class II patients,
or to NYHA class III patients, RVEF remains the best
predictor of event-free survival from cardiovascular death and
urgent transplantation. This demonstrates the usefulness of the
RVEF in the selection of patients at higher risk of events,
whatever the degree of CHF. Right ventricular ejection frac-
tion was the more powerful predictor of survival when we
stratified the population according to etiology or when we
included it in the multivariate model after the previously
documented prognostic parameters, namely, NYHA classifica-
tion, LVEF, peak VO2 normalized to body weight and % of
maximal predicted VO2 (2,4,6). Therefore, RVEF gives addi-
tional independent prognostic information in this subgroup of
patients. The reason why LVEF was not an independent
predictor of cardiac survival is probably because impaired left
ventricular function was an inclusion criterion (LVEF #45%),
whereas RVEF could be normal or abnormal (Fig. 5).
The large number of patients studied and the extremely
high follow-up rate at 1 year allowed us to determine the
sensitivities and specificities for the different values of RVEF
in determining survival at 1 year. Figure 4 shows that a value of
35% gives the highest sensitivity and specificity. Figure 5 shows
the different survival curves as a function of RVEF. There is a
clear relationship between survival and the degree of right
ventricular dysfunction. Patients with an RVEF ,35% are at
higher risk of major cardiac events.
We demonstrated, as did Stelken et al. (4) and DiSalvo et
al. (7), that percent of maximal predicted VO2 is more
powerful than peak VO2 normalized to body weight in predict-
ing survival in patients with advanced heart failure or moderate
heart failure. This result confirms our previous work in which
we demonstrated the independent prediction of survival given
by %peak VO2 (20). However, the advantage of %peak VO2
on peak VO2 normalized to body weight is obtained in some
subgroups of patients (young or old patients, women and
overweight patients). In most of the patients there is an
agreement between %peak VO2 and peak VO2/kg. We have to
keep in mind a value of 50% of maximal predicted VO2 and a
peak VO2 of 10 ml/min/kg as crucial values for the selection of
patients with a high risk of major events at 1 year.
Study limitations. The determination of the RVEF by
radionuclide angiography required a regular ventricular
rhythm, so patients with atrial fibrillation were excluded. Serial
Figure 5. Event-free survival curves from cardiovascular mortality and
urgent transplantation in the three subgroups of patients divided
according to the RVEF ,25%, RVEF between 25 and 35% and
RVEF $35%.
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RVEF determinations will probably increase the power to
predict survival, as it has been demonstrated for LVEF (21).
Systolic pulmonary artery pressure was estimated by the peak
velocity of the tricuspid regurgitation and not by an invasive
method. Because all our patients were ambulatory patients
with stable heart failure, it was not ethical to perform cathe-
terization just to determine cardiac pressures. Our results
cannot be extended to asymptomatic patients with left ventric-
ular systolic dysfunction. Few patients were treated with beta-
blockers, a therapy that is currently extensively investigated
(22–24). It is possible that beta-blockers could change the
relationship between RVEF and survival (as the one between
peak VO2 and survival). We did not include new noninvasive
parameters of prognosis (mitral deceleration time, QT vari-
ability, recovery parameters after a maximal exercise test)
(20,25–27). In the future, it will be important to combine these
parameters in the same population to define the most powerful
prognostic variables. Finally, the evaluation of the systolic and
the diastolic function of the right ventricle by other methods is
currently under investigation. Some new echocardiographic
techniques (automated border detection, tissue Doppler imag-
ing) are promising methods. Probably, in the coming years,
accurate evaluation of right ventricular function will be easily
possible using echocardiography. This would reduce the cost
and simplify the management of patients with CHF. Further
echocardiographic studies are required to evaluate the most
useful parameters to define right ventricular systolic and
diastolic functions.
Conclusion. We demonstrated that in patients with mod-
erate heart failure, RVEF in addition to the NYHA functional
classification and the percent of maximal predicted VO2 was
an independent predictor of survival and of major cardiac
events. The determination of the RVEF in patients with
moderate heart failure, particularly in NYHA class II patients,
seems to be useful to improve their management.
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